<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570956</url>
  </required_header>
  <id_info>
    <org_study_id>19-011444</org_study_id>
    <nct_id>NCT04570956</nct_id>
  </id_info>
  <brief_title>Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ</brief_title>
  <official_title>A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy C. Degnim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to prospectively study breast tissue changes after a short course of&#xD;
      Tamoxifen (Tam).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are at increased&#xD;
      risk of breast cancer (BC) (~1-2 % per year). Over two decades ago, placebo-controlled&#xD;
      randomized trials established that oral tamoxifen (20 mg/day) reduces breast cancer risk by&#xD;
      50% in generally defined high risk women, with ~70% reduction in women at high risk&#xD;
      specifically due to atypical hyperplasia.[1] Years later, the side effects and toxicity of&#xD;
      oral tamoxifen at 20 mg/day remain a significant barrier to its uptake and longterm&#xD;
      compliance.[2, 3] To address the issue of toxicity, two main strategies have been pursued: 1)&#xD;
      using a lower dose of oral tamoxifen, and 2) using a topical formulation of tamoxifen to&#xD;
      avoid systemic side effects. The investigators will perform a prospective study of women with&#xD;
      AH or LCIS who will take a short course of prevention therapy; breast tissue samples will be&#xD;
      evaluated pre- and post-therapy to identify and evaluate very early biomarkers of response.&#xD;
      The overall goal of the study is to evaluate short-term changes in background breast tissue&#xD;
      induced by either low-dose oral tamoxifen or topical 4-OHT gel in women with AH or LCIS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 2:2:1 with either Oral Tamoxifen 10 mg/day&#xD;
gel placebo, Topical 4-OHT gel 2 mg/each breast/day&#xD;
oral placebo, or Control Oral and gel placebo for 4 weeks of treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
    <masking_description>Subjects with be randomized by MedidataRave and Pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The purpose of this research is to evaluate short-term changes in background breast tissue induced by oral tamoxifen or 4-OHT gel in women with atypical hyperplasia or lobular carcinoma in situ (LCIS).</measure>
    <time_frame>48 months</time_frame>
    <description>Treatment Evaluation/Measurement of Effect</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Atypical Hyperplasia</condition>
  <condition>Lobular Carcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>Oral Tamoxifen 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tamoxifen 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day&#xD;
+oral placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral and gel placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Oral Tamoxifen 10 mg/day</description>
    <arm_group_label>Oral Tamoxifen 10 mg/day</arm_group_label>
    <other_name>Oral tamoxifen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day</intervention_name>
    <description>Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day</description>
    <arm_group_label>Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day</arm_group_label>
    <other_name>Topical gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pill or placebo gel</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>placebo pill</other_name>
    <other_name>placebo gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up&#xD;
&#xD;
          -  Willing to complete required testing&#xD;
&#xD;
          -  Ability to complete questionnaire by themselves or with assistance&#xD;
&#xD;
          -  Female (sex that was assigned at birth)&#xD;
&#xD;
          -  Ipsilateral intact breast with histology confirmation of atypical ductal or lobular&#xD;
             hyperplasia, or LCIS, within the last 12 months, whether surgically excised or not.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤1&#xD;
&#xD;
          -  Willingness to agree to use ONE effective form of birth control (abstinence is not an&#xD;
             allowed method) prior to study entry and for the duration of study participation, and&#xD;
             for 2 months following the last dose of study medications. Effective birth control&#xD;
             methods are: copper IUD [intrauterine device], diaphragm/cervical cap/shield,&#xD;
             spermicide, contraceptive sponge, condoms. Women of childbearing potential must have a&#xD;
             negative pregnancy test within five days before starting study medications. Should a&#xD;
             participant become pregnant or suspect she is pregnant while participating in this&#xD;
             study; the participant should inform the study physician immediately.&#xD;
&#xD;
          -  Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e.&#xD;
             tanning beds) for the duration of the study.&#xD;
&#xD;
          -  Participants must have acceptable organ and marrow function as defined below within 30&#xD;
             days of randomization: judged by treating physician's evaluation of baseline&#xD;
             laboratory data.&#xD;
&#xD;
          -  Negative urine pregnancy test, if of childbearing potential. and / or FSH to verify&#xD;
             menopausal status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically suspicious mass/lesions Breast cancer in the past 5 years.&#xD;
&#xD;
          -  Prior thromboembolism within last 5 years (history of varicose veins and superficial&#xD;
             phlebitis is allowed) Current pregnancy or lactation History of other prior breast&#xD;
             cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents,&#xD;
             endocrine agents, everolimus, CDK4-6 inhibitors).&#xD;
&#xD;
          -  Cytotoxic chemotherapy for any indication in last 2 years.&#xD;
&#xD;
          -  Prior use of SERMS or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or&#xD;
             exemestane for prevention or therapy within 5 years.&#xD;
&#xD;
          -  Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to&#xD;
             research core needle biopsy (CNB).&#xD;
&#xD;
          -  Use of vaginally administered estrogens and hormone coated IUD such as Mirena is&#xD;
             permitted History of any prior ipsilateral breast radiotherapy. Previous unilateral&#xD;
             radiation of the contralateral side is allowed.&#xD;
&#xD;
          -  Skin lesions on the breast that disrupt the stratum corneum (eg eczema, ulceration).&#xD;
&#xD;
          -  History of endometrial neoplasia&#xD;
&#xD;
          -  Current smoker. Cessation for at least 6 weeks&#xD;
&#xD;
          -  Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of&#xD;
             tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine.&#xD;
&#xD;
          -  Participants may not be receiving any other investigational agents within 90 days of&#xD;
             enrollment or during this study.&#xD;
&#xD;
          -  History of allergic reactions to tamoxifen.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness that in the judgement of the treating physician&#xD;
             would make them unsuitable for study participation&#xD;
&#xD;
          -  Anticoagulation meds and clinical concern for discontinuing meds for study research&#xD;
             biopsy.&#xD;
&#xD;
          -  Identification of a clinically suspicious mass on examination.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Degnim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denice Gehling, RN</last_name>
    <phone>507-538-1628</phone>
    <email>gehling.denice@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa R Seymour</last_name>
    <email>seymour.lisa@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denice Gehling, RN</last_name>
      <phone>507-538-1628</phone>
      <email>gehling.denice@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Seymour, B.S</last_name>
      <phone>5072727414</phone>
      <email>seymour.lisa@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Degnim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amy C. Degnim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Afimoxifene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

